Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells

Journal of Medicinal Chemistry
2016.0

Abstract

Synergistic-to-additive antileukemic interactions of piperlongumine (PL) and HDAC inhibitor (HDACi) SAHA (Vorinostat) provide a compelling rationale to construct PL-HDACi hybrids, such as 1-58, which recapitulated the synergism between the parental compounds in high-risk and chemoresistant AML cells. Both PL and HDACi components, either in combination or in hybrid molecules, are essential for inducing significant DNA damage and apoptosis. Introducing C2-chloro substituent to 1-58 yielded 3-35 with increased cytotoxicity but decreased selectivity in noncancerous MCF-10A cells; eliminating C7-C8 olefin of PL obtained 3-31/3-98 scaffolds which were still more active than PL or SAHA in AML and were well-tolerated by MCF-10A cells. The HDACi function was crucial for modulating expression of DNA repair and apoptosis-related proteins. Collectively, PL and SAHA hybrids are potent, multifunctional anti-AML agents, acting in part, by interfering cellular GSH defense, suppressing expression of DNA repair and pro-survival proteins, and inducing expression of pro-apoptotic proteins.

Knowledge Graph

Similar Paper

Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells
Journal of Medicinal Chemistry 2016.0
Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line
Nigerian Journal of Clinical Practice 2020.0
Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells
Bioorganic & Medicinal Chemistry 2022.0
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads
Journal of Medicinal Chemistry 2021.0
A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects
European Journal of Medicinal Chemistry 2020.0
Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors
Bioorganic & Medicinal Chemistry Letters 2011.0
Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity
Bioorganic & Medicinal Chemistry Letters 2010.0
Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties
European Journal of Medicinal Chemistry 2016.0
Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues
Bioorganic & Medicinal Chemistry Letters 2007.0
Synthesis and evaluation of N -heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents
European Journal of Medicinal Chemistry 2017.0